NCT03174964View on ClinicalTrials.gov

Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 20, 2016

Primary Completion Date

February 10, 2017

Study Completion Date

September 20, 2017

Conditions
Recurrent Implantation Failure
Interventions
DRUG

IVIg

Patients will take a dose of 400mg/kg of IVIg 2 days before ET.

Trial Locations (1)

Unknown

Alzahra hospital, Tabriz

All Listed Sponsors
lead

Tabriz University of Medical Sciences

OTHER

NCT03174964 - Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure | Biotech Hunter | Biotech Hunter